Emerging Therapies for Viral Hepatitis and Liver Fibrosis

New techniques to prevent and diagnose viral hepatitis C virus (HCV) are evolving exponentially. With  the prelude of interferon‐α monotherapy predicated on triple therapies with pegylated interferon‐α and ribavirin, it increases the percentage of curing patients infected with HCV genotype-1 upto approximately 70%. 
 
Cirrhosis is the end stage of Liver fibrosis which occurs due to series of actions to achieve injurious processes. Doubtlessly, liver fibrosis and cirrhosis are the most common disease globally. 

    Related Conference of Emerging Therapies for Viral Hepatitis and Liver Fibrosis

    July 25-26, 2024

    3rd International Conference on Gastroenterology and Liver

    Amsterdam, Netherlands
    November 21-22, 2024

    23rd World Congress on Gastrointestinal Cancer

    Dubai, UAE

    Emerging Therapies for Viral Hepatitis and Liver Fibrosis Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in